The shaping and functional consequences of the microRNA landscape in breast cancer
- PMID: 23644459
- DOI: 10.1038/nature12108
The shaping and functional consequences of the microRNA landscape in breast cancer
Abstract
MicroRNAs (miRNAs) show differential expression across breast cancer subtypes, and have both oncogenic and tumour-suppressive roles. Here we report the miRNA expression profiles of 1,302 breast tumours with matching detailed clinical annotation, long-term follow-up and genomic and messenger RNA expression data. This provides a comprehensive overview of the quantity, distribution and variation of the miRNA population and provides information on the extent to which genomic, transcriptional and post-transcriptional events contribute to miRNA expression architecture, suggesting an important role for post-transcriptional regulation. The key clinical parameters and cellular pathways related to the miRNA landscape are characterized, revealing context-dependent interactions, for example with regards to cell adhesion and Wnt signalling. Notably, only prognostic miRNA signatures derived from breast tumours devoid of somatic copy-number aberrations (CNA-devoid) are consistently prognostic across several other subtypes and can be validated in external cohorts. We then use a data-driven approach to seek the effects of miRNAs associated with differential co-expression of mRNAs, and find that miRNAs act as modulators of mRNA-mRNA interactions rather than as on-off molecular switches. We demonstrate such an important modulatory role for miRNAs in the biology of CNA-devoid breast cancers, a common subtype in which the immune response is prominent. These findings represent a new framework for studying the biology of miRNAs in human breast cancer.
Similar articles
-
Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.Biomed Res Int. 2015;2015:746970. doi: 10.1155/2015/746970. Epub 2015 Apr 15. Biomed Res Int. 2015. PMID: 25961039 Free PMC article.
-
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control.BMC Genomics. 2013 Sep 23;14:643. doi: 10.1186/1471-2164-14-643. BMC Genomics. 2013. PMID: 24059244 Free PMC article.
-
Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer.Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7413-7. doi: 10.1073/pnas.1304977110. Epub 2013 Apr 15. Proc Natl Acad Sci U S A. 2013. PMID: 23589849 Free PMC article.
-
MicroRNA involvement in the pathogenesis and management of breast cancer.J Clin Pathol. 2009 May;62(5):422-8. doi: 10.1136/jcp.2008.060681. J Clin Pathol. 2009. PMID: 19398594 Review.
-
Small players with big roles: microRNAs as targets to inhibit breast cancer progression.Curr Drug Targets. 2010 Sep;11(9):1059-73. doi: 10.2174/138945010792006762. Curr Drug Targets. 2010. PMID: 20545613 Free PMC article. Review.
Cited by
-
MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells.Cancer Cell Int. 2021 Apr 15;21(1):213. doi: 10.1186/s12935-021-01873-4. Cancer Cell Int. 2021. PMID: 33858435 Free PMC article. Review.
-
Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer.Genome Med. 2021 Apr 29;13(1):72. doi: 10.1186/s13073-021-00880-4. Genome Med. 2021. PMID: 33926515 Free PMC article.
-
Identification and characterization of lncRNA mediated transcriptional dysregulation dictates lncRNA roles in glioblastoma.Oncotarget. 2016 Jul 19;7(29):45027-45041. doi: 10.18632/oncotarget.7801. Oncotarget. 2016. PMID: 26943771 Free PMC article.
-
The role of microRNAs in human breast cancer progression.Tumour Biol. 2014 Jul;35(7):6235-44. doi: 10.1007/s13277-014-2202-8. Epub 2014 Jun 18. Tumour Biol. 2014. PMID: 24938874 Review.
-
miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives.Target Oncol. 2017 Apr;12(2):179-200. doi: 10.1007/s11523-017-0478-5. Target Oncol. 2017. PMID: 28243959 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical